



RESEARCH ARTICLE

Detecting *Mycobacterium ulcerans* in Clinical Specimens from Ghana: Comparative Evaluation of BU-LAMP and IS2404 PCR

Enoch Aninagyei^{1*} , Rufai Tanko² , Comfort Dede Tetteh³ , Kofi Adjei Ntiri⁴ , Mathias Dongyele⁵ , Alex Boye⁶  and Desmond Omame Acheampong⁷ 

¹Department of Biomedical Sciences, School of Basic and Biomedical Sciences, University of Health and Allied Sciences, Ghana

²New Juabeng Municipal Health Directorate, Koforidua, Ghana

³Ga West Municipal Health Directorate, Amasaman, Accra, Ghana

⁴Mayera-Faase Health Centre, Mayera-Faase, Greater Accra Region, Ghana

⁵Ear, Nose and Throat Nursing School, Kumasi, Ashanti Region, Ghana

⁶Department of Medical Laboratory Technology, University of Cape Coast, Ghana

⁷Department of Biomedical Sciences, School of Allied Health Sciences, University of Cape Coast, Ghana

*Corresponding author: Enoch Aninagyei, Department of Biomedical Sciences, School of Basic and Biomedical Sciences, University of Health and Allied Sciences, PMB 31, Ho, Volta Region, Ghana, Tel: +233-244-632496



Abstract

Background: Conventional and nested polymerase chain reaction (PCR), and loop-mediated isothermal amplification (LAMP) have been used to identify *Mycobacterium ulcerans* in separate studies and different specimens. However, the sensitivities of these three techniques have not been compared in a single study.

Objective: This study compared the performance of two variant PCR techniques and LAMP assays to detect *M. ulcerans* in same clinical specimens.

Methods: Samples were collected from patients suspected of Buruli ulcer disease (BUD) in Southern Ghana. Ulcerative and non-ulcerative forms of the disease were swabbed and aspirated respectively. Insertion sequence 2404 (IS2404) *M. ulcerans* targets were detected in each sample using conventional polymerase chain reaction (PCR), nested PCR and loop-mediated isothermal amplification (LAMP) assay.

Results: In all, 141 suspected BUD patients were sampled (Amasaman, n = 52; Obom, n = 17; Paakro, n = 31; Nkawie, n = 21 and Tapa, n = 20). The reference technique, nested PCR, detected *M. ulcerans* in 122 (86.5%) whereas conventional PCR and BU-LAMP detected *M. ulcerans* in 104 (73.7%) and 119 (84.4%) samples respectively. Compared to

nested PCR, conventional PCR performed poorly ($\chi^2 = 19.7$, $p < 0.01$; $\kappa = 0.58$; % agreement = 86.62) while BU-LAMP was as good as nested PCR ($\chi^2 = 0.457$, $p = 0.459$; $\kappa = 0.88$; % agreement = 97.16). Sensitivity of conventional PCR and BU-LAMP were 84.6% (95% CI: 76.9-90.4) and 97.5% (95% CI: 92.9-99.5) respectively. BU-LAMP and nested PCR detected *M. ulcerans* in ulcerative forms of the disease and category II lesions better while the three techniques did not differ in sensitivities in other clinical forms and lesion categories.

Conclusion: BU-LAMP assay is very comparable to nested PCR in detecting *M. ulcerans* from clinical specimens. More importantly, LAMP assay is user-friendly, fast, requires less instrumentation and easy to use in resource-limited laboratory with minimal user training.

Keywords

Mycobacterium ulcerans, BU-LAMP, Nested-PCR, Conventional PCR, Buruli ulcer, Ghana

Abbreviations

BUD: Buruli Ulcer Disease; DNA: Deoxyribonucleic Acid; IS: insertion sequence; LAMP: Loop-Mediated Isothermal Amplification; PCR: Polymerase Chain Reaction

Introduction

Mycobacterium ulcerans causes Buruli ulcer disease (BUD), a tropical skin disease which presents with severe necrosis and chronic cutaneous infection [1]. After *M. ulcerans* inoculation, lesions appear as painless, and mostly ignored by patients [2]. Early stages of the disease present as papules, nodules, plaques and oedema [3]. Which later progresses to ulceration of subcutaneous layers and bones [4], if treatment is delayed.

Due to the disfiguration and lifelong loss of mobility associated with the disease [5], early diagnosis with sensitive, rapid, user-friendly and cheap technique is important. In view of the foregoing, several diagnostic techniques have been developed to improve diagnosis of BUD. Notwithstanding, rapid diagnosis of the disease using sensitive techniques has not been achieved due to various demerits associated with current testing methods. The most common diagnostic methods are Ziehl-Neelson microscopy technique [6], cultivation of the bacilli [7] and molecular detection of insertion sequence 2404 (*IS2404*) using either polymerase chain reactions (PCR) [8] and/or loop-mediated isothermal amplification techniques (LAMP) [9]. Microscopic detection and culture of *M. ulcerans* are very specific, however these techniques are slow (positive culture obtainable in 6-12 weeks and in some cases up to 36 weeks) and of low sensitivity (approx. 40% for microscopy and 20-60% for culture) [6,10,11]. PCR on the other hand is very sensitive [8] but the processes involved are time consuming, delaying results for clinical decision. Again, it is not easily exploited in laboratories of developing countries where the disease is endemic [12]. A quick method for diagnosis of BUD has been developed, based on the loop mediated isothermal amplification (BU-LAMP) technique. As it stands now, three different LAMP assays for laboratory confirmation of BUD have been published [13]. The assay described by de Souza, et al. [9] targeted the enoyl reductase gene of *M. ulcerans*. Enoyl reductase gene is involved in mycolactone synthesis, the most important virulence factor in BUD pathogenesis. However, technical validation of the assay was conducted only on a limited number of samples. Deployment of this assay on a large scale, with samples collected from different locations and from different clinical forms of the disease is essential towards point-of-care application of the LAMP assay. Hence, this study was designed to compare the efficiency of BU-LAMP to the conventional and nested PCR. Even though these techniques have been piloted in separate studies, their sensitivities have not been evaluated using the same set of samples.

Methods

Study sites

Clinical specimens used in this study were collected from major Buruli ulcer clinics in Southern Ghana. Namely, Ga West Municipal Hospital in Amasaman,

Obom Health centre in Obom (Greater Accra Region), Paakro Health Centre in Paakro (Eastern Region), Nkawie-Toase Hospital in Nkawie and Tapa Government Hospital in Tapa (both in Ashanti Region). These health facilities serve as referral sites for Buruli ulcer disease from nine of 16 regions in Ghana.

Sampling techniques

Samples were collected from both ulcerative and non-ulcerative forms of the disease. Non-ulcerative and ulcerative lesions were aspirated using fine needle and swabbed using sterile swab sticks respectively. Both fine needle aspirates and swabs tips with necrotic tissues were put in Eppendorf tubes containing 1 mL of PANTA (polymyxin B, amphotericin B, nalidixic acid, trimethoprim and azlocillin) transport medium. All samples were sent to Bacteriology Department of Noguchi Memorial Institute for Medical Research, University of Ghana for molecular analysis. Demographic parameters as well as clinical forms and categories of the lesions were also taken.

Inclusion and exclusion criteria

Suspected BUD patients included in the study were new patients (patients that have never been treated with anti-BUD drugs or have taken anti-BUD drugs for less than 1 month). Patients with category three lesions at critical sites such as eye, genitals, breast, joints and osteomyelitis were excluded in this study.

Place of laboratory work

DNA extraction, polymerase chain reactions and loop-mediated isothermal amplification assays for all samples were done in the Department of Bacteriology, Noguchi Institute for Medical Research, University of Ghana, Legon-Accra.

DNA extraction using the modified Boom's method

DNA was extracted and purified based on the protocol described by Ablordey, et al. [14]. In brief, Portions 250 µl of the sample suspensions were lysed with 250 µl of lysis buffer (1.6 M GuHCl, 60 mM Tris pH 7.4, 1% Triton X-100, 60 mM EDTA, Tween-20 10%), 50 µl Proteinase-K and 250 µl glass beads. The mixtures were incubated horizontally at 200 rpm at 60 °C overnight. To capture the DNA, 40 µl of diatomaceous earth solution (10g diatomaceous earth obtained from Sigma-Aldrich Chemie GmbH in 50 ml of H₂O containing 500 µl of 37% (wt/vol) HCl) was added to the suspensions and incubated at 37 °C with shaking (200 rpm) for 60 min. The mixtures were centrifuged at 14,000 rpm for 10 sec. and the resulting pellets washed twice with 900 µl of 70% ethanol (2-8 °C) followed by 900 µl of acetone. The pellets were dried at 50 °C for 20 min and resuspended in 100 µl milli Q purified water and centrifuged at 14,000 rpm for 10 sec. The purified DNA was used as templates for both *IS2404* nested-PCR and LAMP assays to detect *M. ulcerans*.

Conventional PCR

Conventional PCR master mix per sample was prepared by adding the constituent reagents as follows; 2 µL Qiagen buffer, 2 µL Q solution, 1.2 µL MgCl₂ (25 mmol/L), 2 µL each deoxynucleoside triphosphate (200 µM), 1 µL forward primer (0.5 µmol/L), 1 µL reverse primer (0.5 µmol/L), 0.2 µL Taq DNA polymerase (HotstarTaq plus), 9 µL nuclease free water, and approximately 50 ng of DNA. The primer sets used were MU1 (5'-GATCAA GC-GTTCACGAGTGA-3') and MU2 (5'-GGCAGTTACTTCACTG-CACA-3') [15]. The PCR reaction mixture was spun shortly to remove water droplets from the inner wall of the PCR tube and inserted into a thermocycler for 40 cycles of DNA denaturation at 96 °C, primer annealing at 60 °C, and oligonucleotide extension at 68 °C. PCR products were electrophoresed in a 1.5% Tris-acetate- EDTA TAE (pH = 8.0) agarose gel with ethidium bromide. The amplicon sizes were estimated by comparison with DNA ladder (Invitrogen, USA) and visualized using Kodak Gel logic 100 imaging system.

IS2404 nested PCR reaction

Due to unavailability of *IS2404* qPCR, nested PCR was used as reference technique to which all other techniques were compared. The *IS2404* sequence was amplified in a 30 µL reaction mixture comprising 15.5 µL nuclease free water, 3 µL PCR buffer, 6.0 µL Q-solution, 2.0 µL dNTPs, 0.1 µL Hotstar Taq DNA pol, 0.3 µL each of pGp1 (pGp1: 5'-AGGGCAGCGCGGTGATACGG-3') and pGp2 (pGp2: 5'-CAGTGGATTGGTGCCGATCGAG-3') primers and 3 µL DNA extract. The first run PCR reaction was done based on these amplification conditions; initial denaturation at 95 °C (15 minutes) and 40 cycles of denaturation, annealing and extension at 94 °C, 64 °C and 75 °C respectively. The second run of the *IS2404* (nested) PCR was performed by using 1 µL of the first run PCR amplicons as the template DNA and 24 µL of master mix. The master mix for the nested reaction was the same as that for the first run PCR except that primer set pGp1 and pGp2 were replaced with the primer set pGp3 (5'-GGCGCAGATCAACTTCGCGGT-3') and pGp4 (5'-CTG-CGTGGTGCTTTACGCGC-3') with the same volume. The same PCR amplification condition was used for the nested PCR except 35 cycles of denaturation, annealing and extension. The primers used have been previously used by Ablordey, et al. [14].

BU-LAMP reaction

The BU-LAMP reaction was made in 25.0 µL volume made up of 12.5µL of reaction mix, 1 µL of fluorescent detector, 2.6 µL of primer mix (FIP: 5'-GCATCTCCG-GCCACCCAACGCCAACGACCGCTA-3'; BIP: 5'-GTG-GTGGGCCCCTGGGAAACCGCTGTGCGAACTGTGC-3'; F3: 5'-ACGGATCGTCGAGGATGG-3'; B3: 5'-GCGCCAGGTC-CCTTGA-3'; FLP: 5'-GAGCCTGCTGGGCGGTGC-3'; BLP: 5'-CATATCCCACCCTGGTG-3'), 1 µL of Bst DNA poly-

merase (Eiken Chemical, Japan), 2.9 µL of nuclease free distilled water (Promega, USA) and 5 µL of the DNA extract in 0.2 ml microAmp™ tubes (Applied Biosystems, Singapore). The DNA amplification was done by incubating the reaction mixture on a heating block at a temperature of 65 °C for 1 hour and the Bst DNA polymerase was inactivated at 80°C for 5 minutes. The BU-LAMP primers used were designed by de-Souza, et al. [9]. The final reactions were determined by visual examination of the final colour production. A final greenish yellow colour development signified a positive reaction and a light brown final colour signified a negative reaction.

Quality control for molecular techniques

For every batch of 20 DNA isolation from clinical samples, two tubes of nucleic free water and two isolates of culture positive samples, found to be positive by *IS2404* PCR, were used as negative and positive extraction controls respectively. Initial screening found the negative and positive controls negative and positive respectively before that batch of DNA from clinical samples were further processed. During the amplification phase of the techniques, another two tubes of nucleic free water and two *IS2404* positive culture samples were used as respective negative and positive amplification controls. A respective corresponding negative and positive amplifications outcome validated all PCR and LAMP assays.

Data analysis

Data were analysed using SPSS Version 24 (Chicago, IL, USA). Differences in categorical data were determined using Chi square whilst Chi square goodness of fit was used to compare the performance of conventional PCR and BU-LAMP to nested PCR. Finally, sensitivities, specificities, positive and negative predictive values and their respective 95% confidence intervals as well as the inter-diagnostic technique test of agreement were determined based on Bayesian model. In all these analysis, significant levels were determined at $p < 0.05$.

Results

Study sites, age and gender distributions of the patients

A total of 141 suspected Buruli ulcer cases were sampled from the five study sites from August 2014 to May 2016. In absolute terms, majority of the cases were sampled from Ga West Municipal Hospital (46, 32.6%), Amasaman while minority of the cases sampled were seen in Obom Health Centre (17, 12.0%), Obom. Majority of the suspected cases were males (65.9%) and patients aged less than 19 years (36.9%). In all study areas, 80.0% or more of the suspected cases were confirmed to be infected with Buruli ulcer disease (BUD). High prevalence of BUD was also seen in both males and females with patients aged 0-19 years disproportionately affected (94.2%) (Table 1).

Table 1: Distribution of Buruli ulcer cases by study sites, gender and age group of patients (yrs).

Variable (number of suspected BUD cases)	Number (%) confirmed positive by nested PCR	Number (%) confirmed negative by nested PCR	p-value
Study site			0.568
Ga West Hospital (n = 52)	46 (88.5%)	6 (11.5%)	
Nkawie-Toase Hospital (n = 21)	19 (90.5%)	2 (9.5%)	
Obom Health Centre (n = 17)	16 (94.1%)	1 (5.9%)	
Paakro Health Centre (n = 31)	25 (80.6%)	6 (19.4%)	
Tepa Govt Hospital (n = 20)	16 (80.0%)	4 (20.0%)	
Gender			0.201
Male (n = 93)	83 (89.2%)	10 (10.8%)	
Female (n = 48)	39 (81.3%)	9 (18.7%)	
Age group (yrs.)			0.0002
0-19 (n = 52)	49 (94.2%)	3 (5.8%)	
20-39 (n = 31)	27 (87.1%)	4 (12.9%)	
40-59 (n = 43)	37 (86.0%)	6 (13.0%)	
60-79 (n = 10)	8 (80.0%)	2 (20.0%)	
80 + (n = 5)	1 (20.0%)	4 (80.0%)	

p-values determined by Chi square at 95% confidence interval.

Table 2: Comparative performance analysis of the diagnostic techniques.

Diagnostic Technique	Positivity Rate n (%)	Negativity Rate n (%)	Chi square goodness of fit χ^2 (p-value)
Nested IS2404 PCR	122 (86.5%)	19 (13.5%)	-
Conventional IS2404 PCR	104 (73.8%)	37 (26.25)	19.7 (p < 0.001)
BU-LAMP assay	119 (84.4%)	22 (15.6)	0.547 (p = 0.459)

Chi square goodness of fit was determined at 95% confidence interval.

Clinical forms of the disease, category of lesions and type of samples collected

Out of the 141 samples collected, 73% were ulcerative lesions, 16.3 were nodular lesions and 10.6% were oedematous form of the disease. Per the clinical forms of the disease encountered, swab samples were collected from ulcerative form of the disease while fine needle aspiration was done on the nodular and oedematous forms of the disease (27%). All the three categories of the disease were encountered; category I lesions (single lesions < 5 cm in diameter [5]) were 64 (45.3%), category II lesions (single lesions between 5-15 cm diameter [5]) were 24 (17.0%) and category III lesions (either a single lesion more than 15 cm diameter or multiple lesions or lesions at critical sites such as eye, genitals, breast, joints [5]) were 53 (37.6%).

Positivity rate of the techniques

Nested PCR detected *M. ulcerans* in 122 (86.5%) of the 141 samples tested while conventional PCR and BU-LAMP detected *M. ulcerans* in 104 (73.8%) and 119 (84.4%) samples tested respectively. Compared to nested PCR, the performance of conventional PCR was statistically different ($\chi^2 = 19.7$, p < 0.01) while the performance of nested PCR did not differ from BU-LAMP assay ($\chi^2 = 0.457$, p = 0.459) (Table 2).

Sensitivity and specificity of the diagnostic techniques

The diagnostic performance of BU-LAMP and conventional PCR to detect *M. ulcerans* using nested PCR results as reference technique are presented in Table 3. The sensitivity of BU-LAMP was higher than conventional PCR even though both techniques were of equal specificity. According to the interpretation of Cohen's kappa values by McHugh [16], there was a strong agreement between nested PCR and BU-LAMP ($\kappa = 0.88$) whilst nested PCR agreed with conventional PCR weakly ($\kappa = 0.58$).

Analysis of the efficiency of the protocols on clinical forms and lesions categorization

The performance of the three diagnostic techniques to detect *M. ulcerans* in ulcerative forms of the disease was significantly different. The performance of the techniques differed in their ability to detect *M. ulcerans* in ulcerative lesions ($\chi^2 = 9.68$, p = 0.008) but not in nodular ($\chi^2 = 1.81$, p = 0.403) and oedematous forms of the disease ($\chi^2 = 2.50$, p = 0.286). Nested-PCR and BU-LAMP detected *M. ulcerans* in equal number of ulcerative samples so as nodular samples. But BU-LAMP did not detect *M. ulcerans* in oedematous lesion as compared

Table 3: Diagnostic indices and how nested PCR agreed with Bu-LAMP and conventional PCR.

Indices	BU-LAMP	Conventional PCR
True positive	119	104
True negative	19	19
False positive	0	0
False negative	3	19
Sensitivity (95% CI)	97.5% (92.9-99.5%)	84.6% (76.9-90.4%)
Specificity (95% CI)	100.0 (82.35-100.0)	100.0 (82.35-100.0)
PPV (95% CI)	100.0	100.0
NPV (95% CI)	86.4% (67.4-95.1%)	50.00% (39.81-60.19%)
Kappa value	0.88% (0.564-0.741)	0.59% (0.51-0.69)
% agreement	97.16	86.62

Values in parenthesis is 95% confidence interval.

Table 4: Performance of the techniques on clinical forms and categories of the disease.

	Nested IS2404 PCR		Conventional IS2404 PCR		BU-LAMP		χ^2 (p-value)
	Positive n (%)	Negative n (%)	Positive n (%)	Negative n (%)	Positive n (%)	Negative n (%)	
Clinical forms of lesions							
Ulcer (n = 103)	89 (86.4%)*	14 (13.6%)	74 (71.8%)	29 (28.2%)	89 (86.4%)*	14 (13.6%)	9.68 (0.008)
Nodule (n = 23)	20 (87.0%)	3 (13.0%)	17 (74.0%)	6 (26.0%)	20 (87.0%)	3 (13.0%)	1.81 (0.403)
Oedema (n = 15)	13 (86.7%)	2 (13.3%)	13 (86.7%)	2 (13.3%)	10 (66.7%)	5 (33.3%)	2.50 (0.286)
Categorization of lesions							
Category I (n = 64)	58 (90.6)	6 (9.4%)	55 (86.0%)	9 (14.0%)	58 (90.6%)	6 (9.7%)	0.96 (0.618)
Category II (n = 24)	21 (87.5)*	3 (12.5%)	13 (54.2%)	11 (45.8%)	21 (87.5%)*	3 (12.5%)	6.82 (0.033)
Category III (n = 53)	43 (81.1)	10 (18.9%)	36 (67.9%)	17 (23.1%)	40 (75.5%)	13 (24.5%)	2.47 (0.290)

*No significant difference between techniques at significant level of 0.05. P-values were determined by Chi square at significant level 0.05. Category I lesions are single lesions < 5 cm in diameter; category II lesions are single lesions between 5-15 cm diameter; category III lesions are either a single lesion more than 15 cm diameter or multiple lesions [5].

to the other two techniques. Also, there were differences in the ability of the techniques to detect *M. ulcerans* in category II lesions but nested-PCR and BU-LAMP detected *M. ulcerans* in category II lesions with equal ability. In category I and III lesions, the techniques had equal ability to detect *M. ulcerans* in their samples (Table 4).

Discussion

The sensitivity of three molecular techniques for the diagnosis of Buruli ulcer disease (BUD) is reported herein. Nested-PCR detected more infections in the clinical specimens than BU-LAMP and conventional PCR. However, BU-LAMP was superior to conventional PCR. The positivity rates for the techniques reflected in the sensitivities of the techniques. Comparing to nested-PCR, BU-LAMP was more sensitive than conventional PCR. However, the techniques were of equal specificities. Furthermore, nested-PCR performed better on all the categories and clinical forms of the disease. This study presents an alternative to laboratory diagnosis of BUD. Laboratory confirmation of BUD is a better diagnostic option compared to the widely used clinical diagnosis which represents a challenge due to the vast number of other skin infections or conditions that may present

symptoms similar to that of BUD [17]. In furtherance to this, World Health Organization (WHO) has directed that all suspected cases of BUD are confirmed in the laboratory [18].

The performance of the three diagnostic techniques to detect *M. ulcerans* in ulcerative forms of the disease significantly differed from the other. While nested-PCR and Bu-LAMP performed very well on ulcerative lesions ($\chi^2 = 9.68$, $p = 0.008$), the techniques were comparable on nodular lesions ($\chi^2 = 1.81$, $p = 0.403$) and oedematous forms of the disease ($\chi^2 = 2.50$, $p = 0.286$). Also, there were differences in the ability of the techniques to detect *M. ulcerans* in category II lesions but nested-PCR and BU-LAMP detected *M. ulcerans* in category II lesions with equal ability. In category I and III lesions, the techniques had equal ability to detect *M. ulcerans* in their samples. Detection of insertion sequence (IS) elements in *Mycobacterium* spp have been reported in several studies [19-21]. ISs are species specific, and multiple copies have been detected within one genome, facilitating a highly specific and sensitive detection of the respective pathogens. Ross, et al. [8] first provided a milestone for the PCR-based diagnosis of BUD by identifying an *M. ulcerans*-specific repetitive DNA fragment

which was later characterized in detail and designated *IS2404* [22]. There are about 150-200 copies of *IS2404* per *M. ulcerans* genome [23]. These large copies of *IS2404* predestine their application as targets for sensitive molecular amplification tests for *M. ulcerans*.

On the other hand, loop-mediated isothermal amplification (LAMP) is a molecular method, which is relatively cheaper, simpler and faster compared to the PCR. The LAMP technology has been developed to detect several pathogens such as *Trypanosoma* species [24], *Cryptosporidium* species [25], *Toxoplasma gondii* [26], *Babesia microti* [27], *Taenia* species [28], *Mycobacterium tuberculosis* [29], *Plasmodium* spp [30] and rift valley fever virus [31]. In this study, LAMP assay was as good as nested PCR. This is because LAMP assays have been found to be very sensitive with the ability to detect as low as 20 - 30 copies of the ISs (about 0.1 to 0.15 genome of *M. ulcerans*) [32]. The analytical sensitivity of BU-LAMP has been found to be higher than conventional PCR [33] though lower than qPCR [34]. But equipment sophistication and the level of expertise needed to perform qPCR technique makes BU-LAMP an alternative choice in developing countries with resource limited settings. LAMP assays have several advantages over PCR assays. Comparing LAMP to PCR, it was realized that LAMP technology is less expensive in the sense that less instrumentation is required to achieve amplification at isothermal temperatures. Results obtained by LAMP were obtained within 1 hour but in the case of *IS2404* PCR, the turnaround time was over 5 hours. Aside high sensitivity of BU-LAMP over PCR, the technique has been found to amplify DNA target from partially processed or unprocessed specimen [35]. Detection of LAMP products was found to be easy due to large amount of dsDNA formed and production of magnesium pyrophosphate allow visual detection of reactions. Considering the nature of LAMP technique, it is highly feasible in the field. These features associated with LAMP have been previously published [24,32,36,37].

In *Plasmodium falciparum* infections, analytical positive and negative rate of LAMP method was equivalent to that of nested-PCR methods [38]. These reports make LAMP assay a potential technique to replace PCR based techniques as a confirmation technique for infectious agents. Due to the specific nature of the action of LAMP primers, the amount of DNA produced is considerably higher than PCR based amplification. The corresponding release of pyrophosphate results in visible turbidity which allows easy visualization of amplification products [39]. LAMP has been observed to be less sensitive than PCR to inhibitors in complex samples such as blood, possibly due to the use of a different DNA polymerase (*Bst* DNA polymerase rather than *Taq* polymerase as in PCR). Several reports have described successful detection of pathogens from minimally processed samples [40,41]. This feature of LAMP may be useful in low-re-

source or field settings where a conventional DNA or RNA extraction prior to diagnostic testing may be impractical [42]. Also LAMP technique has been evaluated for point-of-care use to detected several pathogens [43-45]. Therefore, LAMP has the potential to be used as a point-of-care technique to detect *M. ulcerans* both in the laboratory and in the field.

Conclusion

This study has demonstrated that BU-LAMP is as good as nested PCR, hence it can be used as a reliable molecular technique to detect *M. ulcerans* infections from clinical samples. It is recommended that LAMP based assays be used at facilities in endemic communities to detect *M. ulcerans* in suspected lesions because it promised to perform well in resource-limited laboratories. Suffice it to say, LAMP assays have been found to be very cheap, user-friendly, rapid, highly sensitive and above all easy to read amplification reactions.

Acknowledgments

Authors want to acknowledge the administrators and medical directors of Ga West Hospital, Nkawie-Toase Hospital, Obom Health Centre, Paakro Health Centre and Tepa Government Hospital. Also the role of the respective district disease control officers in identification of the cases and the various roles played by the laboratory managers in charge of the various hospital facilities with respect to this study are appreciated. Finally, authors are thankful to Noguchi Institute for Medical Research, Accra, Ghana for providing facilities to carry out the laboratory work. We are also grateful to Dr D. K. De-Souza and Dr Anthony Ablordey for facilitating the acquisition of the reagents and other consumables used in this study. Finally, we are thankful to Prof Alexander Debrah for supervising this study.

Source of Funding

This work was funded from authors own resources.

References

1. Fyfe JAM, Lavender CJ, Handasyde KA, Legione AR, O'Brien CR, et al. (2010) A major role for mammals in the ecology of *Mycobacterium ulcerans*. *PLoS Negl Trop Dis* 4: e791.
2. Asiedu K, Sherpbier R, Raviglione MC, WHO Global Buruli Ulcer Initiative (2000) Buruli ulcer: *Mycobacterium ulcerans* Infection. World Health Organization, Geneva, Switzerland, 1-118.
3. Bamberger D, Jantzer N, Leidner K, Arend J, Efferth T (2011) Fighting mycobacterial infections by antibiotics, phytochemicals and vaccines. *Microbes Infect* 13: 613-623.
4. Silva MT, Portaels F, Pedrosa J (2009) Pathogenetic mechanisms of the intracellular parasite *Mycobacterium ulcerans* leading to Buruli ulcer. *Lancet Infect Dis* 9: 699-710.
5. Agbenorku P, Edusei A, Agbenorku M, Diby T, Nyador E, et al. (2012) Buruli-ulcer induced disability in Ghana: A Study at Aprozase in the Ashanti Region. *Plast Surg Int* 752749.

6. Phillips C, Horsfield C, Kuijper S, Lartey A, Tetteh I, et al. (2005) Sensitivity of PCR targeting the IS2404 insertion sequence of *Mycobacterium ulcerans* in an assay using punch biopsy specimens for diagnosis of buruli ulcer. *J Clin Microbiol* 43: 3650-3656.
7. Portaels F, Aguiar J, Fissette K, Fonteyne PA, De Beenhouwer H, et al. (1997) Direct detection and identification of *Mycobacterium ulcerans* in clinical specimens by PCR and oligonucleotide-specific capture plate hybridization. *J Clin Microbiol* 35: 1097-1100.
8. Ross BC, Marino L, Oppedisano F, Edwards R, Robins-Browne RM, et al. (1997) Development of a PCR assay for rapid diagnosis of *Mycobacterium ulcerans* infection. *J Clin Microbiol* 35: 1696-1700.
9. De-Souza DK, Quaye C, Mosi L, Addo P, Boakye DA (2012) A quick and cost effective method for the diagnosis of *Mycobacterium ulcerans* infection. *BMC Infect Dis* 12: 8-15.
10. King CH, Ashford DA, Dobos KM, Whitney EA, Raghunathan PL, et al. (2001) *Mycobacterium ulcerans* infection and Buruli ulcer disease: Emergence of a public health dilemma. In: Scheld WM, Craig WA, Hughes JM, Emerging infections. A Soc Microbiol Press, Washington, 9: 137-152.
11. Buntine J, Kimball C (2001) Buruli ulcer: Management of *Mycobacterium ulcerans* disease: A manual for health care providers. World Health Organization 4.
12. Monteiro L, Bonnemaïson D, Vekris A, Petry KG, Bonnet J, et al. (1997) Complex polysaccharides as PCR inhibitors in feces: *Helicobacter pylori* model. *J Clin Microbiol* 35: 995-998.
13. Beissner M, Phillips RO, Battke F, Bauer M, Badziklou K, et al. (2015) Loop-mediated isothermal amplification for laboratory confirmation of buruli ulcer disease-towards a point-of-care test. *PLoS Negl Trop Dis* 9: e0004219.
14. Ablordey A, Amisshah DA, Aboagye IF, Hatano B, Yamazaki T (2012) Detection of *Mycobacterium ulcerans* by the loop mediated isothermal amplification method. *PLoS Negl Trop Dis* 6: e1590.
15. Lavender CJ, Fyfe JAM (2013) Direct detection of *Mycobacterium ulcerans* in clinical specimens and environmental samples. *Methods Mol Biol* 943: 201-216.
16. McHugh ML (2012) Interrater reliability: The kappa statistic. *Biochem Med (Zagreb)* 22: 276-282.
17. Semret M, Koromihis G, MacLean JD, Libman M, Ward BJ (1999) *Mycobacterium ulcerans* infection (Buruli ulcer): First reported case in a traveller. *Am J Trop Med Hyg* 61: 689-693.
18. World Health Organization (2008) Buruli ulcer: Progress report, 2004-2008. *Wkly Epidemiol Rec* 17: 145-154.
19. Hermans PW, van Soolingen D, Dale JW, Schuitema AR, McAdam RA, et al. (1990) Insertion element IS986 from *Mycobacterium tuberculosis*: A useful tool for diagnosis and epidemiology of tuberculosis. *J Clin Microbiol* 28: 2051-2058.
20. Thierry D, Brisson-Noel A, Vincent-Levy-Frebault V, Nguyen S, Guesdon JL, et al. (1990) Characterization of a *Mycobacterium tuberculosis* insertion sequence, IS6110, and its application in diagnosis. *J Clin Microbiol* 28: 2668-2673.
21. Kang TJ, Kim SK, Lee SB, Chae GT, Kim JP (2003) Comparison of two different PCR amplification products (the 18-kDa protein gene vs. RLEP repetitive sequence) in the diagnosis of *Mycobacterium leprae*. *Clin Exp Dermatol* 28: 420-424.
22. Stinear T, Ross BC, Davies JK, Marino L, Robins-Browne RM, et al. (1999) Identification and characterization of IS2404 and IS2606: Two distinct repeated sequences for detection of *Mycobacterium ulcerans* by PCR. *J Clin Microbiol* 37: 1018-1023.
23. Doig KD, Holt KE, Fyfe JA, Lavender CJ, Eddyani M, et al. (2012) On the origin of *Mycobacterium ulcerans*, the causative agent of Buruli ulcer. *BMC Genomics* 13: 258.
24. Kuboki N, Inoue N, Sakurai T, Di Cello F, Grab DJ, et al. (2003) Loop-mediated isothermal amplification for detection of African trypanosomes. *J Clin Microbiol* 41: 5517-5524.
25. Karanis P, Thekisoe O, Kiouptsi K, Ongerth J, Igarashi I, et al. (2007) Development and preliminary evaluation of a loop-mediated isothermal amplification procedure for sensitive detection of *Cryptosporidium* oocysts in fecal and water samples. *Appl Environ Microbiol* 73: 5660-5662.
26. Sotiriadou I, Karanis P (2008) Evaluation of loop-mediated isothermal amplification for detection of *Toxoplasma gondii* in water samples and comparative findings by polymerase chain reaction and immunofluorescence test (IFT). *Diagn Microbiol Infect Dis* 62: 357-365.
27. Guan G, Chauvin A, Luo J, Inoue N, Moreau E, et al. (2008) The development and evaluation of a loop-mediated isothermal amplification (LAMP) method for detection of *Babesia* spp. infective to sheep and goats in China. *Exp Parasitol* 120: 39-44.
28. Nkouawa A, Sako Y, Nakao M, Nakaya K, Ito A (2009) Loop-mediated isothermal amplification method for differentiation and rapid detection of *Taenia* species. *J Clin Microbiol* 47: 168-174.
29. Tomotada I, Toshiaki S, Kozaburo H (2003) Loop-mediated isothermal amplification for direct detection of *Mycobacterium tuberculosis* Complex, *M. avium*, and *M. intracellulare* in Sputum Samples. *J Clin Microb* 41: 2616-2622.
30. Aninagyei E, Smith-Graham S, Boye A, Egyir-Yawson A, Acheampong DO (2019) Evaluating 18s-rRNA LAMP and selective whole genome amplification (sWGA) assay in detecting asymptomatic *Plasmodium falciparum* infections in blood donors. *Malar J* 18: 214.
31. Peyrefitte CN, Boubis L, Coudrier D, Bouloy M, Grandadam M, et al. (2008) Real-time reverse-transcription loop-mediated isothermal amplification for rapid detection of rift valley fever virus. *J Clin Microbiol* 46: 3653-3659.
32. Njiru ZK, Yeboah-Manu D, Stinear TP, Fyfe JAM (2012) Rapid and sensitive detection of *Mycobacterium ulcerans* by use of a loop-mediated isothermal amplification test. *J Clin Microbiol* 50: 1737-1741.
33. Siegmund V, Adjei O, Racz P, Berberich C, Klutse E, et al. (2005) Dry reagent-based PCR as a novel tool for laboratory confirmation of clinically diagnosed *Mycobacterium ulcerans*-associated disease in areas in the tropics where *M. ulcerans* is endemic. *J Clin Microbiol* 43: 271-276.
34. Fyfe JAM, Lavender CJ, Johnson PDR, Globan M, Sievers A, et al. (2007) Development and application of two multiplex real-time PCR assays for the detection of *Mycobacterium ulcerans* in clinical and environmental samples. *Appl Environ Microbiol* 73: 4733-4740.
35. Kaneko H, Kawana T, Fukushima E (2007) Tolerance of loop-mediated isothermal amplification to a culture medium and biological substances. *J Biochem Biophys Methods* 70: 499-501.
36. Poon LLM, Wong BWY, Ma EHT, Chan KH, Chow LMC, et al. (2006) Sensitive and inexpensive molecular test for

- falciparum malaria: Detecting *Plasmodium falciparum* DNA directly from heat-treated blood by loop-mediated isothermal amplification. *Clin Chem* 52: 303-306.
37. Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K, et al. (2000) Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res* 28: E63-E65.
38. Imai K, Tarumoto N, Misawa K, Runtuwene LR, Sakai J, et al. (2017) A novel diagnostic method for malaria using loop-mediated isothermal amplification (LAMP) and MinION™ nanopore sequencer. *BMC Infect Dis* 17: 621.
39. Ngotho M, Kagira JM, Gachie BM, Karanja SM, Waema MW, et al. (2015) Loop mediated isothermal amplification for detection of *Trypanosoma brucei gambiense* in urine and saliva samples in nonhuman primate model. *BioMed Res Int* 2015: 867846.
40. Mori Y, Kitao M, Tomita N, Notomi T (2004) Real-time turbidimetry of LAMP reaction for quantifying template DNA. *J Biochem Biophys Methods* 59: 145-157.
41. Curtis KA, Rudolph DL, Owen SM (2008) Rapid detection of HIV-1 by reverse-transcription, loop-mediated isothermal amplification (RT-LAMP). *J Virol Methods* 151: 264-270.
42. Sattabongkot J, Tsuboi T, Han ET, Bantuchai S, Buates S (2014) Loop-mediated isothermal amplification assay for rapid diagnosis of malaria infections in an area of endemicity in Thailand. *J Clin Microbiol* 52: 1471-1477.
43. Serra-Casas E, Manrique P, Ding XC, Carrasco-Escobar G, Alava F, et al. (2017) Loop-mediated isothermal DNA amplification for asymptomatic malaria detection in challenging field settings: Technical performance and pilot implementation in the Peruvian Amazon. *PLoS One* 12: e0185742.
44. de Paz HD, Brotons P, Munoz-Almagro C (2014) Molecular isothermal techniques for combating infectious diseases: Towards low-cost point-of-care diagnostics. *Expert Rev Mol Diagn* 14: 827-843.
45. Niemz A, Ferguson TM, Boyle DS (2011) Point-of-care nucleic acid testing for infectious diseases. *Trends Biotechnol* 29: 240-250.